Table 2.

Univariate and multivariable analyses of predictors of pCR breast and pCR breast/axilla

	N	ORa	95% CI	p Value
Univariate analysis
pCR breast
Age at diagnosis	97	1.02	0.98–1.05	0.434
Menopausal status	90	1.06	0.45–2.52	0.895
Family history of breast cancer	71	0.34	0.13–0.90	0.030
Tumor type	97	0.91	0.65–1.26	0.557
Tumor grade	97	0.15	0.05–0.47	0.001
Basal statusb	91	0.63	0.18–2.26	0.477
Platinum-based NACT	95	0.38	0.16–0.91	0.030
pCR breast/axilla
Age at diagnosis	97	1.01	0.98–1.05	0.454
Menopausal status	90	1.1	0.45–2.67	0.833
Family history of breast cancer	71	0.51	0.19–1.32	0.162
Tumor grade	97	0.08	0.02–0.36	0.001
Tumor type	97	1.04	0.73–1.48	0.815
Basal statusb	91	0.49	0.12–1.95	0.311
Platinum-based NACT	95	0.32	0.13–0.79	0.013
Multivariable analysis
pCR breast	95
Age at diagnosis		1.00	0.96–1.05	0.892
Tumor grade		0.10	0.03–0.37	0.001
Platinum-based NACT		0.26	0.09–0.74	0.011
pCR breast/axilla	95
Age at diagnosis		1.01	0.97–1.05	0.704
Tumor grade		0.05	0.01–0.27	< 0.001
Platinum-based NACT		0.17	0.06–0.54	0.002

n Number of patients, OR odds ratio, CI confidence interval, NACT neoadjuvant chemotherapy, pCR pathological complete response

^aOR for a non-pCR by Logistic regression analysis

^bBasal status: any positivity for either cytokeratin 5/6 or EGFR by immunohistochemistry